Founded in 2019 as a spin-off of CNRS and Reims University (UMR 7369 MEDyC), Apmonia Therapeutics is a biotechnology company at the forefront of anti-cancer immunotherapy. Boasting an executive team comprised of seasoned members from research institutes and the biotech industry, Apmonia Therapeutics is dedicated to developing innovative strategies for combating cancer, with a specific focus on tumours that overexpress the matricellular protein thrombospondin-1 (TSP-1). The company’s visionary approach involves a personalized methodology, combining their proprietary therapeutic peptide, TAX2 peptide, with a companion diagnostic kit. This kit serves the crucial purpose of patient stratification, relying on monitoring circulating TSP-1 levels. By blending cutting-edge science and personalized medicine, Apmonia Therapeutics aims to make significant strides in cancer treatment.